Cite
MLA Citation
J Mark FitzGerald et al.. “Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.” Lancet, vol. 388, no. 10056, 2016, pp. 2128–2141. http://access.bl.uk/ark:/81055/vdc_100038840260.0x00001a